- Home
- GRND vs RCKT Comparison
GRND vs RCKT Comparison
Compare GRND & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRND
- RCKT
- Stock Information
- Founded
- GRND 2009
- RCKT 1999
- Country
- GRND United States
- RCKT United States
- Employees
- GRND N/A
- RCKT N/A
- Industry
- GRND Computer Software: Prepackaged Software
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- GRND Technology
- RCKT Health Care
- Exchange
- GRND Nasdaq
- RCKT Nasdaq
- Market Cap
- GRND 2.1B
- RCKT 1.9B
- IPO Year
- GRND N/A
- RCKT N/A
- Fundamental
- Price
- GRND $13.65
- RCKT $17.13
- Analyst Decision
- GRND Strong Buy
- RCKT Strong Buy
- Analyst Count
- GRND 3
- RCKT 9
- Target Price
- GRND $15.33
- RCKT $53.22
- AVG Volume (30 Days)
- GRND 464.9K
- RCKT 731.3K
- Earning Date
- GRND 11-07-2024
- RCKT 11-04-2024
- Dividend Yield
- GRND N/A
- RCKT N/A
- EPS Growth
- GRND N/A
- RCKT N/A
- EPS
- GRND N/A
- RCKT N/A
- Revenue
- GRND $300,034,000.00
- RCKT N/A
- Revenue This Year
- GRND $30.64
- RCKT N/A
- Revenue Next Year
- GRND $21.70
- RCKT $300.20
- P/E Ratio
- GRND N/A
- RCKT N/A
- Revenue Growth
- GRND 34.98
- RCKT N/A
- 52 Week Low
- GRND $5.71
- RCKT $15.98
- 52 Week High
- GRND $13.90
- RCKT $32.53
- Technical
- Relative Strength Index (RSI)
- GRND 63.17
- RCKT 46.41
- Support Level
- GRND $13.06
- RCKT $17.05
- Resistance Level
- GRND $13.90
- RCKT $17.75
- Average True Range (ATR)
- GRND 0.42
- RCKT 0.72
- MACD
- GRND 0.06
- RCKT 0.06
- Stochastic Oscillator
- GRND 80.54
- RCKT 40.23
About GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.